Sales of 10 Chinese medicines soared: 癀, even flowers clear plague, blue herring oral solution...

Medicine Network December 18, the latest forecast data show that 2020E China's urban brick-and-mortar drugstore terminal sales of traditional Chinese medicines reached 105.4 billion yuan, down 5.5% year-on-year.
29 exclusive Chinese medicine annual sales of more than 300 million (4 more than 1 billion), 5 fewer than last year; 4 enterprises involved in the number of varieties up to 2 and above.
provinces and cities to launch a pilot collection of Chinese medicine, will provide experience for national medicine, Chinese medicine medical institutions market will face more uncertainty, retail pharmacies or into a new battleground. Table
: 2020E China's urban physical pharmacy terminal sales of more than 300 million yuan of exclusive Chinese medicine source: Minet China's urban physical pharmacy terminal competition pattern Minet forecast data show that 29 exclusive Chinese medicine (in terms of drug name, including exclusive dosage form) in 2020 China's urban physical pharmacy terminal Sales of more than 300 million yuan, a decrease of 5 compared to 2019 (Chuanbei Sydney syrup, Ding Guier umbilical paste, turtle age set, children's sage heat particles, Su Huang cough capsules), involving Yangzijiang, Yunnan white medicine, China Resources Medicine, Tianshili and other 24 pharmaceutical companies (in group terms).
Figure 1: 29 exclusive Chinese medicine treatment categories from the treatment category, 29 exclusive Chinese medicine covers 8 treatment categories, respiratory diseases drug use is the leading, accounting for 24.14 percent, skeletal muscle system disease medication with 17.24 percent of the proportion followed by urological disease medication, digestive disease medication with 13.79 percent of the third.
"One brother" easy owner, 4 exclusive Chinese medicine more than 1 billion Shijiazhuang Yiling Pharmaceuticals Lianhua Qing plague capsules, Kyoto Ing TzuGeneral Factory of Kyoto Ing Tzu Honey-refined Sichuan bay paste, Yangzijiang Pharmaceuticals' blue-knut oral solution, Guangzhou Baiyunshan Chen Liji Pharmaceutical Factory With sales of more than 1 billion yuan, the company ranked 6, 8, 10, and 11th in the 2020E Chinese city physical pharmacies with a market share of 1.22%, 1.12%, 1.08% and 1.0%, respectively.
in the 2020E Chinese city physical pharmacy terminal cough phlegm flat wheezing drug, Kyoto Ingci honey-refined Sichuan beetle paste with 14.18% market share in the first place In the drug competition pattern, the oral solution of blue herring leads with 23.33 percent market share, and in the competitive pattern of skeletal musculoskeletal disease drug use, the shulu jian waist pill leads with 10.96 percent market share.
2 exclusive Traditional Chinese medicine for the first time exceeded 1 billion yuan, for Shijiazhuang Toling Pharmaceuticals Lianhua Qing plague capsules (growth rate of 108.1%) and Yangzijiang Pharmaceuticals' blue slug oral solution (growth rate of 20.9%), of which Lianhua Qing plague capsules will replace Kyoto Ingci
even flower clear plague capsule has the effect of detoxifying the plague, venting the lung fever, mainly used for the treatment of influenza is a hot poison attack lung certificate.
this product is a new Chinese medicine developed by Ling Pharmaceuticals during the "SARS" period in 2003, for the national medical insurance Class A varieties, the national base medicine, approved in April 2020 for the regular treatment of new crown pneumonia.
driven by the sales of epidemic prevention and control drugs, Lianhua Qing plague capsules are expected to exceed 1 billion yuan for the first time in 2020, up 108.1% year-on-year.
Figure 2: China's urban physical pharmacy terminal blue stamen oral liquid sales (unit: 10,000 yuan) Source: Minet China's urban physical pharmacy terminal competition pattern blue stamen oral solution has the effect of detoxifying heat, pharynx detoxification, can be used for acute pharyngitis, pulmonary heart fever caused by pharynx pain, dry pharynx, pharynx fever, etc., for the national health insurance category B varieties.
In recent years, the sales of oral fluids in physical pharmacies in Chinese cities have increased year by year, accounting for the proportion of the throat drug market has increased year by year, and sales are expected to exceed 1 billion yuan for the first time in 2020, an increase of 20.94 percent year-on-year, accounting for 23.33 percent of the throat drug market.
10 exclusive Chinese medicine rising against the trend, Yunnan white medicine, Tiansli... According to the forecast data of 4 enterprises, the sales of Chinese medicines in the terminals of physical pharmacies in China's cities in 2020 were 105.4 billion yuan, down 5.5% YoY, while the total sales of 29 exclusive Chinese medicines with sales of more than 300 million yuan exceeded 16 billion yuan, down 7% YoY.
10 exclusive Chinese medicine "counter-trend" rise, including lianhua Qing plague capsules, blue herring oral liquid, tablets , iron maple dou particles 4 varieties growth rate of more than 10%.
Figure 3: China's urban physical drugstore terminal tablets sales situation (units: 10,000 yuan) Source: Mi Net China's urban physical pharmacies terminal competition pattern tablets with clear heat detoxification, cold hemorrhoids, anti-swelling pain effect, clinically can be used for anthraxsores, nameless swelling, swelling injury, acute hepatitis, eye inflammation, otitis and other inflammatory pain, fever and other effects.
meters intranet data show that in China's urban physical pharmacy terminal hepatitis drug market, the chiphas been at the top of the list, and the market share is increasing year by year, is expected to achieve sales revenue of nearly 900 million yuan in 2020, an increase of 16.85 percent year-on-year.
figure 4: Sales of more than 300 million yuan of exclusive Chinese medicine number of 2 or more enterprises 29 sales of more than 300 million yuan of exclusive Chinese traditional medicine involving 24 pharmaceutical companies (in group terms), including Yunnan White Medicine, China Resources Pharmaceuticals, Sanjin Pharmaceuticals, Tiansli 4 enterprises with 2 varieties and above.
Yunnan White Medicine leads with 3 exclusive Chinese medicines, namely Yunnan White Medicine Aerosol, Yunnan White Ointment, Yunnan White Medicine, and Yunnan White Medicine, and China Resources Pharmaceutical has 2 exclusive Chinese medicine sales of more than 300 million yuan, respectively, compound a gum slurry (National Health Insurance Class B varieties), three Nine stomach Thai particles; Tiansli's compound Dansan drop pills (national health insurance Class A varieties), wearing heart lotus ester drop pills (National Health Insurance Class B varieties) are exclusive dosage forms; Three Gold Pharmaceuticals' Guilin watermelon cream for the national health insurance Class B varieties, three gold tablets for the National Health Insurance Class A varieties.
chinese medicine collection in the future attack, retail pharmacies or into a new battlefield? The fourth batch of national collection on December 12 officially launched the report, a total of 44 products, 90 product regulations, the collection is still mainly chemical drugs, involving a number of anti-sugar drugs, anti-tumor drugs and injections, previously the attention of biological products and Chinese medicine is not included in the list.
this year, the State Health Insurance Administration has repeatedly "named" biological products and Chinese medicine in the collection and harvesting.
On the issue of Chinese medicine collection, the State Health Insurance Administration said on November 30, will guide and promote local research on Chinese medicine and other drugs, while Qinghai Province, Zhejiang Jinhua, Henan Puyang and other places for some of the large demand, high amount of Chinese medicine collection results have been affirmed.
Overall, the current provincial and local market collection, chemical drugs are still mainstream, but the State Health Insurance Administration mentioned Qinghai, Henan, Zhejiang Jinhua and other provinces and cities have carried out their own exploration of The collection of Chinese medicine - June 8, Jinhua City, Zhejiang Province, issued a paper to carry out the second batch of drug belt procurement, involving 274 varieties, the total purchase amount 600 million yuan, of which 180 Chinese medicine, including Lianhua Qing plague capsules, Pudi blue anti-inflammatory oral solution, Yunnan white medicine aerosols and capsules, ox yellow on the clear capsule, clearing the ling particles, dredging detoxification capsules, ginseng injection, strong dew, six-flavored yellow pills, Kangai injection and so on.
On June 24, Qinghai Province issued the "Quantity Purchased Medicines Catalog (First Batch)", involving a total of 59 drugs (in serial numbers), including Magpie injections, injection of blood plugs (freeze-dried), injections of dansan polyphenols and other large varieties of Chinese medicine injections.
July 22, Liaoning Province issued a message, will carry out with volume procurement of 13 varieties, involving gas and blood kang oral solution, Yunnan white medicine hemorrhoid cream, the first vera pass capsules, children's wood to clear particles, joint analgesic barb paste, anti-ointment, pro-lyne cream 7 Chinese medicine.
August 19, Henan Province issued a notice on the relevant pharmaceutical product information filling work, to 31 drugs to be centralized procurement, including seven-leaf sodium saponin, glucosin, Sichuan and other Chinese medicine.
, Zhejiang Jinhua, Qinghai, Liaoning, Henan and other provinces and cities to launch the Chinese medicine belt procurement pilot, will provide experience for Chinese medicine national procurement.
if Chinese medicine is included in the national harvest, overlaying reasonable drug use, medical insurance payment reform and other policies, the market of Chinese medicine medical institutions will face more uncertainty, retail pharmacies or become a new battleground.
sources: Mi-net database, provincial and municipal recruitment platform